Jump to content

Kava

From Wikipedia, the free encyclopedia
(Redirected from Yaqona)

This article is about the plant. For the class of pharmacological derivatives, see Kavalactone. For other uses, see Kava (disambiguation).

Kava
Piper methysticum leaves
Scientific classification Edit this classification
Kingdom: Plantae
Clade: Tracheophytes
Clade: Angiosperms
Clade: Magnoliids
Order: Piperales
Family: Piperaceae
Genus: Piper
Species:
P. methysticum
Binomial name
Piper methysticum

Kava or kava kava (Piper methysticum: Latin 'pepper' and Latinized Greek 'intoxicating') is a plant in the pepper family, native to the Pacific Islands.[1] The name kava is from Tongan and Marquesan, meaning 'bitter.’[1] Other names for kava include ʻawa (Hawaiʻi),[2] ʻava (Samoa), yaqona or yagona (Fiji),[3] sakau (Pohnpei),[4] seka (Kosrae),[5] and malok or malogu (parts of Vanuatu).[6] Kava can refer to either the plant or a beverage made from its root. The beverage has sedative, anesthetic, psychoactive and euphoriant properties. It is consumed throughout the Pacific Ocean cultures of Polynesia, including Hawaii and Vanuatu, Melanesia, some parts of Micronesia, such as Pohnpei and Kosrae, and the Philippines.

Kava consists of sterile cultivars clonally propogated from its wild ancestor, Piper wichmanii.[6] It originated in northern Vanuatu, where it was domesticated by farmers around 3,000 years ago through selective cultivation.[7] Historically, fresh kava was consumed; dry kava consumption emerged in response to the efforts of Christian missionaries in the 18th and 19th centuries to prohibit the drinking of kava.[8]

Its active compounds are known as kavalactones.[9] Systematic reviews and meta-analyses conducted in the last decade have typically indicated a modest positive effect of kava on anxiety and Generalized Anxiety Disorder, though the evidence is mixed and further research is frequently recommended.[10][11][12][13][14][15]

Moderate consumption of kava in its traditional form, as a water-based suspension of kava roots, is considered by the World Health Organization to present an “acceptably low level of health risk.”[16] However, consumption of kava extracts produced with organic solvents or excessive amounts of low-quality kava products may be linked to an increased risk of adverse health outcomes, including liver injury.[16][17][18]

History and names

[edit]
See also: Domesticated plants and animals of Austronesia

Kava is conspecific with Piper wichmannii, indicating Kava was domesticated from Piper wichmannii (syn. Piper subbullatum).[19][20]

It was spread by the Austronesian Lapita culture after contact eastward into the rest of Polynesia. It is endemic to Oceania and is not found in other Austronesian groups. Kava reached Hawaii, but it is absent in New Zealand, where it cannot grow.[20][21][22] Consumption of kava is also believed to be the reason why betel nut chewing, ubiquitous elsewhere, was lost for Austronesians in Oceania.[23]

According to Lynch (2002), the reconstructed Proto-Polynesian term for the plant, *kava, was derived from the Proto-Oceanic term *kawaR in the sense of a "bitter root" or "potent root [used as fish poison]". It may have been related to reconstructed *wakaR (in Proto-Oceanic and Proto-Malayo-Polynesian) via metathesis. It originally referred to Zingiber zerumbet, used to make a similar mildly psychoactive bitter drink in Austronesian rituals. Cognates for *kava include Pohnpeian sa-kau; Tongan, Niue, Rapa Nui, Tuamotuan, and Rarotongan kava; Samoan, Tahitian, and Marquesan ʻava; and Hawaiian ʻawa. In some languages, most notably Māori kawa, the cognates have come to mean "bitter", "sour", or "acrid" to the taste.[20][24][25][26]

In the Cook Islands, the reduplicated forms of kawakawa or kavakava are also applied to the unrelated members of the genus Pittosporum. In other languages, such as Futunan, compound terms like kavakava atua refer to other species belonging to the genus Piper. The reduplication of the base form is indicative of falsehood or likeness, in the sense of "false kava".[27][22] In New Zealand, it was applied to the kawakawa (Piper excelsum), which is endemic to New Zealand and nearby Norfolk Island and Lord Howe Island. It was exploited by the Māori based on previous knowledge of the kava, as the latter could not survive in the colder climates of New Zealand. The Māori name for the plant, kawakawa, is derived from the same etymon as kava, but reduplicated. It is a sacred tree among the Māori people. It is seen as a symbol of death, corresponding to the rangiora (Brachyglottis repanda), which is the symbol of life. However, kawakawa has no psychoactive properties. Its connection to kava is linked to its similarity in appearance and bitter taste.[27]

Characteristics

[edit]

Kava was historically grown only in the Pacific islands of Hawaii, Federated States of Micronesia, Vanuatu, Fiji, the Samoas, and Tonga. It appears to have originated in Vanuatu; an inventory of P. methysticum distribution showed it was cultivated on numerous islands of Micronesia, Melanesia, Polynesia, and Hawaii, whereas specimens of P. wichmannii were all from Papua New Guinea, the Solomon Islands, and Vanuatu.[28]

Traditionally, plants are harvested around four years of age, as older plants have higher concentrations of kavalactones. After reaching about 2 metres (6.6 ft) in height, plants grow a wider stalk and additional stalks, but not much taller. The roots can reach a depth of 60 centimetres (2.0 ft).

Cultivars

[edit]
Painting showing women preparing kava by John La Farge (c. 1891).

Kava consists of sterile cultivars cloned from its wild ancestor, Piper wichmanii.[6] Today it comprises hundreds of different cultivars grown across the Pacific. Each cultivar has not only different requirements for successful cultivation, but also displays unique characteristics both in terms of its appearance and its psychoactive properties.[6]

Noble and non-noble kava

[edit]

Scholars make a distinction between the so-called noble and non-noble kava. The latter category comprises the so-called tudei (or "two-day") kavas, medicinal kavas, and wild kava (Piper wichmanii, the ancestor of domesticated Piper methysticum).[6][29] Traditionally, only noble kavas have been used for regular consumption, due to their more favourable composition of kavalactones and other compounds that produce more pleasant effects and have lower potential for causing negative side effects, such as nausea, or "kava hangover".[6][17]

The perceived benefits of noble cultivars explain why only these cultivars were spread around the Pacific by Polynesian and Melanesian migrants, with presence of non-noble cultivars limited to the islands of Vanuatu, from which they originated.[6] More recently, it has been suggested that the widespread use of tudei cultivars in the manufacturing of several kava products might have been the key factor contributing to the rare reports of adverse reactions to kava observed among the consumers of kava-based products in Europe.[17]

Tudei varieties have traditionally not been grown in Hawaii and Fiji, but in recent years there have been reports of farmers attempting to grow "isa" or "palisi" non-noble cultivars in Hawaii, and of imports of dried tudei kava into Fiji for further re-exporting.[30] The tudei cultivars may be easier and cheaper to grow: while it takes up to 5 years for noble kava to mature, non-noble varieties can often be harvested just one year after being planted.

The concerns about the adverse effects of non-noble varieties, produced by their undesirable composition of kavalactones and high concentrations of potentially harmful compounds (flavokavains, which are not present in any significant concentration in the noble varieties), have led to legislation prohibiting exports from countries such as Vanuatu.[17] Likewise, efforts have been made to educate non-traditional customers about the difference between noble and non-noble varieties and that non-noble varieties do not offer the same results as noble cultivars.[31][32] In recent years, government regulatory bodies and non-profit NGOs have been set up with the declared aim of monitoring kava quality; producing regular reports; certifying vendors selling proper, noble kava; and warning customers against products that may contain tudei varieties.[33]

Growing regions

[edit]

In Vanuatu, exportation of kava is strictly regulated. Only cultivars classified as noble are allowed to be exported. Only the most desirable cultivars for everyday drinking are classified as noble to maintain quality control. In addition, their laws mandate that exported kava must be at least five years old and farmed organically. Their most popular noble cultivars are "Borogu" or "Borongoru" from Pentecost Island, "Melomelo" from Aoba Island (called Sese in the north Pentecost Island), and "Palarasul" kava from Espiritu Santo. In Vanuatu, Tudei ("two-day") kava is reserved for special ceremonial occasions and exporting it is not allowed. "Palisi" is a popular Tudei variety.

In Hawaii, there are many other cultivars of kava (Hawaiian: ʻawa). Some of the most popular cultivars are Mahakea, Moʻi, Hiwa, and Nene. The Aliʻi (kings) of precolonial Hawaii coveted the Moʻi variety, which had a strong cerebral effect due to a predominant amount of the kavalactone kavain. This sacred variety was so important to them that no one but royalty could ever experience it, "lest they suffer an untimely death". The reverence for Hiwa in old Hawaiʻi is evident in this portion of a chant recorded by Nathaniel Bright Emerson and quoted by E. S. Craighill and Elizabeth Green Handy: "This refers to the cup of sacramental ʻawa brewed from the strong, black ʻawa root (ʻawa hiwa), which was drunk sacramentally by the kumu hula":

The day of revealing shall see what it sees:
A seeing of facts, a sifting of rumors,
An insight won by the black sacred 'awa,
A vision like that of a god![34]

Winter describes a hula prayer for inspiration that contains the line, He ʻike pū ʻawa hiwa. Pukui and Elbert translated this as "a knowledge from kava offerings". Winter explains that ʻawa, especially of the Hiwa variety, was offered to hula deities in return for knowledge and inspiration.[34]

More recently, specialized kava varieties have been introduced to South Florida which have been acclimated and adapted to grow well in South Florida's unique soil and climate and have significant resistance to pest and disease pressures. As of 2024, cultivation of these varieties is limited to a small number of commercial farms and backyard growers.

Relationship with kawakawa

[edit]
Kawakawa (Piper excelsum) plant may have been named by early Polynesian voyagers to New Zealand due to its similarities to kava.

The Kawakawa (Piper excelsum) plant, known also as "Māori kava", may be confused with kava. While the two plants look similar and have similar names, they are different, but related, species. Kawakawa is a small tree endemic to New Zealand, having importance to traditional medicine and Māori culture. As noted by the Kava Society of New Zealand, "in all likelihood, the kava plant was known to the first settlers of Aotearoa [New Zealand]. It is also possible that (just like the Polynesian migrants that settled in Hawaii) the Maori explorers brought some kava with them. Unfortunately, most of New Zealand is simply too cold for growing kava and hence the Maori settlers lost their connection to the sacred plant."[35] Further, "in New Zealand, where the climate is too cold for kava, the Maori gave the name kawa-kawa to another Piperaceae M. excelsum, in memory of the kava plants they undoubtedly brought with them and unsuccessfully attempted to cultivate. The Maori word kawa also means "ceremonial protocol", recalling the stylized consumption of the drug typical of Polynesian societies".[6] Kawakawa is commonly used in Maori traditional medicine for the treatment of skin infections, wounds, and cuts, and (when prepared as a tea) for stomach upsets and other minor illnesses.[36]

Composition

[edit]

Fresh kava root contains on average 80% water. Dried root contains approximately 43% starch, 20% dietary fiber, 15% kavalactones,[9] 12% water, 3.2% sugars, 3.6% protein, and 3.2% minerals.

In general, kavalactone content is greatest in the roots and decreases higher up the plant into the stems and leaves.[9] Relative concentrations of 15%, 10%, and 5% have been observed in the root, stump, and basal stems, respectively.[5] The relative content of kavalactones depends not only on plant segment but also on the kava plant variety, plant maturity, geographic location, and time of harvest.[9] The kavalactones present are kavain, demethoxyyangonin, and yangonin, which are higher in the roots than in the stems and leaves, with dihydrokavain, methysticin, and dihydromethysticin also present.[9]

The mature roots of the kava plant are harvested after a minimum of four years (at least five years, ideally) for peak kavalactone content. Most kava plants produce around 50 kg (110 lb) of root when they are harvested. Kava root is classified into two categories: crown root (or chips) and lateral root. Crown roots are the large-diameter pieces that look like 1.5 to 5 inches (38 to 127 mm)-diameter wooden poker chips. Most kava plants consist of approximately 80% crown root upon harvesting. Lateral roots are smaller-diameter roots that look more like a typical root. A mature kava plant is about 20% lateral roots. Kava lateral roots have the highest content of kavalactones in the kava plant. "Waka" grade kava is made of lateral roots only.

Pharmacology

[edit]

Constituents

[edit]
The general structure of the kavalactones, without the R1-R2 -O-CH2-O- bridge and with all possible C=C double bonds shown.

A total of 18 different kavalactones (or kavapyrones) have been identified to date, at least 15 of which are active.[37] However, six of them, including kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin, have been determined to be responsible for about 96% of the plant's pharmacological activity.[37] Some minor constituents, including three chalcones — flavokavain A, flavokavain B, and flavokavain C — have also been identified,[37] as well as a toxic alkaloid (not present in the consumable parts of the plant[38]), pipermethystine.[39] Alkaloids are present in the roots and leaves.[40]

Pharmacodynamics

[edit]

The following pharmacological actions have been reported for kava and/or its major active constituents:[41]

Receptor binding assays with botanical extracts have revealed direct interactions of leaf extracts of kava (which appear to be more active than root extracts) with the GABA (i.e., main) binding site of the GABAA receptor, the D2 receptor, the μ- and δ-opioid receptors, and the H1 and H2 receptors.[43][44] Weak interaction with the 5-HT6 and 5-HT7 receptors and the benzodiazepine site of the GABAA receptor was also observed.[43]

Potentiation of GABAA receptor activity may underlie the anxiolytic effects of kava, while elevation of dopamine levels in the nucleus accumbens likely underlie the moderately psychotropic effects the plant can produce. Changes in the activity of 5-HT neurons could explain the sleep-inducing action.[45] However, failure of the GABAA receptor inhibitor flumazenil to reverse the anxiolytic effects of kava in mice suggests that benzodiazepine-like effects are not contributing to the pharmacological profile of kava extracts.[46]

Heavy, long-term use of kava has been found to be free of association with reduced ability in saccade and cognitive tests, but has been associated with elevated liver enzymes.[47]

Detection

[edit]

Recent usage of kava has been documented in forensic investigations by quantitation of kavain in blood specimens. The principal urinary metabolite, conjugated 4'-OH-kavain, is generally detectable for up to 48 hours.[48]

Preparations

[edit]
Kava root drying in Lovoni village, Ovalau, Fiji (2005)

Traditional preparation

[edit]

Kava is consumed in various ways throughout the Pacific Ocean cultures of Polynesia, Vanuatu, Melanesia, and some parts of Micronesia and Australia. Traditionally, it is prepared by either chewing, grinding, or pounding the roots of the kava plant. Grinding is done by hand against a cone-shaped block of dead coral; the hand forms a mortar and the coral a pestle. The ground root/bark is combined with only a little water, as the fresh root releases moisture during grinding. Pounding is done in a large stone with a small log. The product is then added to cold water and consumed as quickly as possible.

The extract is an emulsion of kavalactone droplets in starch. The taste is slightly pungent, while the distinctive aroma depends on whether it was prepared from dry or fresh plant, and on the variety. The colour is grey to tan to opaque greenish.

Kava prepared as described above is much more potent than processed kava. Chewing produces the strongest effect because it produces the finest particles. Fresh, undried kava produces a stronger beverage than dry kava. The strength also depends on the species and techniques of cultivation.

In Vanuatu, a strong kava drink is normally followed by a hot meal or tea. The meal traditionally follows some time after the drink so that the psychoactives are absorbed into the bloodstream more quickly. Traditionally, no flavoring is added.

In Papua New Guinea, the locals in Madang province refer to their kava as waild koniak ("wild cognac" in English).

Fijian kava ceremony being performed for tourists (2015). Traditionally, kava grog is drunk from the shorn half-shell of a coconut, called a bilo.[49]

Fijians commonly share a drink called grog, made by pounding sun-dried kava root into a fine powder, straining and mixing it with cold water. Traditionally, grog is drunk from the shorn half-shell of a coconut, called a bilo. Grog is very popular in Fiji, especially among young men, and often brings people together for storytelling and socializing. Drinking grog for a few hours brings a numbing and relaxing effect to the drinker; grog also numbs the tongue, and grog drinking typically is followed by a "chaser" or sweet or spicy snack to follow a bilo.

Kava root being prepared for consumption in Asanvari village on Maewo Island, Vanuatu (2006).

Supplements and pharmaceutical preparations

[edit]

Water extraction is the traditional method for preparation of the plant. Pharmaceutical and herbal supplement companies extract kavalactones from the kava plant using solvents such as supercritical carbon dioxide,[50] acetone, and ethanol to produce pills standardized with between 30% and 90% kavalactones.[33]

Concerns

[edit]

Numerous scholars[51] and regulatory bodies[52][53] have raised concerns over the safety profile of such products.

One group of scholars say that organic solvents introduce compounds that may affect the liver into the standardized product; these compounds are not extracted by water and are consequently largely absent from kava prepared with water.[54] For instance, when compared with water extraction, organic solvents extract vastly larger amounts of flavokavains, compounds associated with adverse reactions to kava that are present in very low concentrations in noble kava, but significant in non-noble.[55][17]

Also, "chemical solvents used do not extract the same compounds as the natural water extracts in traditional use. The extraction process may exclude important modifying constituents soluble only in water".[54] In particular, it has been noted that, unlike traditional water-based preparations, products obtained with the use of organic solvents do not contain glutathione, an important liver-protecting compound.[56] Another group of researchers noted: "The extraction process (aqueous vs. acetone in the two types of preparations) is responsible for the difference in toxicity as extraction of glutathione in addition to the kava lactones is important to provide protection against hepatotoxicity".[56]

It has also been argued that kavalactone extracts have often been made from low-quality plant material, including the toxic aerial parts of the plant that contain the hepatotoxic alkaloid Pipermethystine, non-noble kava varieties, or plants affected by mold — which, in light of the chemical solvents' ability to extract far greater amounts of the potentially toxic compounds than water, makes them particularly problematic.

In the context of these concerns, the World Health Organization advises against the consumption of ethanolic and acetonic kavalactone extracts, and says that "products should be developed from water-based suspensions of kava".[53] The government of Australia prohibits the sales of such kavalactone extracts, and only permits the sale of kava products in their natural form or produced with cold water.[57]

Kava culture

[edit]
A sign showing a "Kava licence area" at Yirrkala, in the Northern Territory of Australia.
Main article: Kava culture

Kava is used for medicinal, religious, political, cultural, and social purposes throughout the Pacific. These cultures have a great respect for the plant and place a high importance on it. In Fiji, for example, a formal yaqona (kava) ceremony will often accompany important social, political, or religious functions, usually involving a ritual presentation of the bundled roots as a sevusevu (gift) and drinking of the yaqona itself.[58][59] Due to the importance of kava in religious rituals and the seemingly (from the Western point of view) unhygienic preparation method, its consumption was discouraged or even banned by Christian missionaries.[6]

Kava bars

[edit]
See also: Nakamal

With kava's increasing popularity, bars serving the plant in its liquid state are beginning to open up outside of the South Pacific.[17][60]

While some bars have been committed to only serving the traditional forms and types of kava, other establishments have been accused of serving non-traditionally consumed non-noble kava varieties, which are cheaper but far more likely to cause unpleasant effects and adverse reactions, or of serving kava with other substances, including alcohol.[61]

Effects of consumption

[edit]

The nature of effects will largely depend on the cultivar of the kava plant and the form of its consumption.[62] Traditionally, only noble kava cultivars have been consumed, as they are accepted as safe and produce desired effects.[63] The specific effects of various noble kavas depend on various factors, such as the cultivar used (and the related specific composition of kavalactones), age of the plant, and method of consumption.[62] However, it can be stated that in general, noble kava produces a state of calmness, relaxation, and well-being without diminishing cognitive performance.[6][64][65] Kava may produce an initial talkative period, followed by muscle relaxation and eventual sleepiness.[66]

As noted in one of the earliest Western publications on kava (1886): "A well prepared Kava potion drunk in small quantities produces only pleasant changes in behavior. It is therefore a slightly stimulating drink which helps relieve great fatigue. It relaxes the body after strenuous efforts, clarifies the mind and sharpens the mental faculties".[67] There are three types of kava, “heady”, “heavy” and “balanced” which all come with different effects. Overall “heady” kava produces more euphoric, uplifting, and stimulating effects and is preferred over “heavy” kava for socializing as it doesn’t cause drowsiness that is associated with “heavy” kava and makes you more social. “Heavy” kava on the other hand makes you more relaxed and is known for its deep relaxation and sedative effects and is preferred for aiding in sleep disorders and people needing more relaxation. Compared to “heady” kava it is not preferred for daytime use due to its sedative effects. “Balanced” kava on the other hand is for anyone wanting to experience “the full range” of kava’s effects as it’s effects are a mix of both “heady” and “heavy” kava.

Despite its psychoactive effects, kava is not considered to be physically addictive and its use does not lead to dependency.[68][69]

Toxicity, safety, and potential side effects

[edit]

General observations

[edit]

There is limited safety information available on the effects of kava consumption, but in general, moderate consumption appears unlikely to be harmful, while there is evidence of harm from heavy use.[16]

Effects on the liver

[edit]

There is published evidence of the hepatotoxicity of kava extracts, and concerns about this led to kava being omitted from the US Pharmacopeia.[70]

Other adverse reactions

[edit]

Adverse reactions may result from the poor quality of kava raw material used in the manufacturing of various kava products.[33][40][71][51] In addition to the potential for hepatotoxicity, adverse reactions from chronic use may include visual impairment, rashes or dermatitis, seizures, weight loss, and malnutrition, but there is only limited high-quality research on these possible effects.[16][40]

On the basis of research findings and long history of safe use across the South Pacific, experts recommend using water-based extractions of high-quality peeled rhizome and roots of the noble kava cultivars to minimize the potential of adverse reactions to chronic use.[16][33]

Potential interactions

[edit]

Several adverse interactions with drugs have been documented, both prescription and nonprescription — including, but not limited to, anticonvulsants, alcohol, anxiolytics (central nervous system depressants such as benzodiazepines), antipsychotics, levodopa, diuretics, and drugs metabolized by CYP450 in the liver.[40]

A few notable potential drug interactions are, but are not limited to:

  • Alcohol: It has been reported that combined use of alcohol and kava extract can have additive sedative effects.[40][72] Regarding cognitive function, kava has been shown to have additive cognitive impairments while taken with alcohol when compared to taking placebo and alcohol alone.[73]
  • Anxiolytics (CNS depressants such as benzodiazepines and barbiturates): Kava may have potential additive CNS depressant effects (such as sedation and anxiolytic effects) with benzodiazepines and barbiturates.[40][73] Kava taken in combination with alprazolam can cause a semicomatose state in humans.[74]
  • Dopamine agonist — levodopa: One of levodopa's chronic side effects that Parkinson's patients experience is the "on-off phenomenon" of motor fluctuations, where there will be periods of oscillations between "on", where the patient experiences symptomatic relief, and "off", where the therapeutic effect wears off early.[75] When taking levodopa and kava together, it has been shown that there is an increased frequency of this "on-off phenomenon".[76]

Kava dermopathy

[edit]

Long-term and heavy kava consumption is associated with a reversible skin condition known as "kava dermopathy", or kanikani (in the Fijian language), characterised by dry and scaly skin covering the palms of the hands, soles of the feet, and back.[40][77][78] The first symptom to appear is usually dry, peeling skin; some Pacific Islanders deliberately consume large quantities of kava for several weeks in order to get the peeling effect, resulting in a layer of new skin.[79] These effects appeared at consumption levels between 31 grams (1.1 oz) to 440 grams (0.97 lb) a week of kava powder. Despite numerous studies, the mechanism that causes kava dermopathy is poorly understood "but may relate to interference with cholesterol metabolism".[78] The condition is easily treatable with abstinence or lowering of kava intake as the skin appears to be returning to its normal state within a couple of weeks of reduced or no kava use.[78] Kava dermopathy should not be confused with rare instances of allergic reactions to kava that are usually characterised by itchy rash or puffy face.[80]

Research

[edit]

Kava is under preliminary research for its potential psychoactive[37] — primarily anxiolytic — sleep-inducing, and sleep-enhancing properties.[81] Preliminary analysis of kava effects in people with short-term anxiety disorders indicated a small level of improvement.[82]

Traditional medicine

[edit]
A traditional Fijian yaqona bundle of roots

Over centuries, kava has been used in the traditional medicine of the South Pacific Islands for central nervous system and peripheral effects.[83] As noted in one literature review: "Peripherally, kava is indicated in traditional Pacific medicine for urogenital conditions (gonorrhea infections, chronic cystitis, difficulty urinating), reproductive and women's health (...), gastrointestinal upsets, respiratory ailments (asthma, coughs, and tuberculosis), skin diseases and topical wounds, and as an analgesic, with significant subtlety and nuance attending the precise strain, plant component (leaf, stem, root) and preparative method to be used".[83]

Regulation

[edit]

Kava remains legal in most countries. Regulations often treat it as a food or dietary supplement.

Australia

[edit]

In Australia, the supply of kava is regulated through the National Code of Kava Management.[84] Travellers to Australia are allowed to bring up to 4 kg of kava in their baggage, provided they are at least 18 years old and the kava is in root or dried form. Commercial import of larger quantities is allowed, under licence for medical or scientific purposes. These restrictions were introduced in 2007 after concern about abuse of kava in indigenous communities. Initially, the import limit was 2 kg per person; it was raised to 4 kg in December 2019, and a pilot program allowing for commercial importation was implemented on 1 December 2021.[85][86]

The Australian Therapeutic Goods Administration has recommended no more than 250 mg of kavalactones be taken in a 24‑hour period.[87]

Kava possession is limited to 2 kg per adult in the Northern Territory.[88][89] While it was previously banned in Western Australia in the 2000s, the Western Australian Health Department announced the lifting of the ban in February 2017, bringing Western Australia "into line with other States" where it has always remained legal, albeit closely regulated.[90]

Europe

[edit]

Following discussions on the safety of certain pharmaceutical products derived from kava and sold in Germany, the EU imposed a temporary ban on imports of kava-based pharmaceutical products in 2002. The sale of kava plant became regulated in Switzerland, France, and in prepared form in the Netherlands.[91] Some Pacific island states which had been benefiting from the export of kava to the pharmaceutical companies have attempted to overturn the EU ban on kava-based pharmaceutical products by invoking international trade agreements at the WTO: Fiji, Samoa, Tonga, and Vanuatu argued that the ban was imposed with insufficient evidence.[92] The pressure prompted Germany to reconsider the evidence base for banning kava-based pharmaceutical products.[93] On 10 June 2014, the German Administrative Court overturned the 2002 ban, making selling kava as a medicine legal (personal possession of kava has never been illegal), albeit strictly regulated. In Germany, kava-based pharmaceutical preparations are currently prescription drugs. Furthermore, patient and professional information brochures have been redesigned to warn about potential side effects.[94] These strict measures have been opposed by some of the leading kava scientists. In early 2016, a court case was filed against the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM/German Federal Institute for Drugs and Medical Devices), arguing that the new regulatory regime is too strict and not justified.[95]

In the United Kingdom, it is a criminal offence to sell, supply, or import any medicinal product containing kava for human consumption.[96] It is legal to possess kava for personal use or to import it for purposes other than human consumption (e.g., for animals).

Until August 2018, Poland was the only EU country with an "outright ban on kava" and where the mere possession of kava was prohibited and may have resulted in a prison sentence.[97] Under the new legislation, kava is no longer listed among prohibited substances and it is therefore legal to possess, import, and consume the plant,[98] but it remains illegal to sell it within Poland for the purpose of human consumption.[99]

In the Netherlands, for unknown reasons, the ban was never lifted, and it is still prohibited to prepare, manufacture, or trade kava or goods containing kava.[100]

New Zealand

[edit]

When used traditionally, kava is regulated as a food under the Food Standards Code. Kava may also be used as an herbal remedy, where it is currently regulated by the Dietary Supplements Regulations. Only traditionally consumed forms and parts of the kava plant (i.e., pure roots of the kava plant, water extractions prepared from these roots) can legally be sold as food or dietary supplements in New Zealand. The aerial parts of the plant (growing up and out of the ground), unlike the roots, contain relatively small amounts of kavalactones; instead, they contain a mildly toxic alkaloid, pipermethysticine.[52] While not normally consumed, the sale of aerial plant sections and non-water based extract (such as CO2, acetonic, or ethanol extractions) is prohibited for the purpose of human consumption (but can be sold as an ingredient in cosmetics or other products not intended for human consumption).[101][102]

North America

[edit]

In 2002, Health Canada issued an order prohibiting the sale of any product containing kava.[103] While the restrictions on kava were lifted in 2012,[104] Health Canada lists five kava ingredients as of 2017.[105][106]

In 2002, the U.S. Food and Drug Administration issued a Consumer Advisory: "Kava-Containing Dietary Supplements May be Associated with Severe Liver Injury". No legal action was taken, and this advisory has since been archived.[107]

Vanuatu

[edit]

The Pacific island-state of Vanuatu has passed legislation to regulate the quality of its kava exports. Vanuatu prohibits the export or consumption of non-noble kava varieties or the parts of the plant that are unsuitable for consumption (such as leaves and stems).[108]

See also

[edit]

References

[edit]
  1. ^ a b "Kava". Merriam–Webster Online Dictionary. 2018.
  2. ^ "Nā Puke Wehewehe ʻŌlelo Hawaiʻi". wehewehe.org. Retrieved 22 December 2017.
  3. ^ "Embassy of the Republic of Fiji". www.fijiembassy.be. Archived from the original on 10 June 2018. Retrieved 22 December 2017.
  4. ^ Balick, Michael J. and Leem, Roberta (2002) Traditional use of sakau (kava) in Pohnpei: lessons for integrative medicine Alternative Therapies, Vol. 8, No.4. p. 96
  5. ^ a b Lebot V, Merlin M, Lindstrom L (23 December 1992). Kava. Yale University Press. doi:10.2307/j.ctt211qwxb. ISBN 978-0-300-23898-3.
  6. ^ a b c d e f g h i j Lebot V, Merlin M, Lindstrom L (1997). Kava: The Pacific Elixir: The Definitive Guide to Its Ethnobotany, History, and Chemistry. Inner Traditions / Bear & Co. p. 58. ISBN 978-0-89281-726-9.
  7. ^ Vincent Lebot, Patricia Siméoni (2004). "Is the Quality of Kava (Piper methysticum Forst. f.) Responsible for Different Geographical Patterns?" (PDF). Ethnobotany Research & Applications. 2: 19–28. doi:10.17348/era.2.0.19-28.
  8. ^ Vincent Lebot, Patricia Siméoni (2004). "Is the Quality of Kava (Piper methysticum Forst. f.) Responsible for Different Geographical Patterns?" (PDF). Ethnobotany Research & Applications. 2: 19–28. doi:10.17348/era.2.0.19-28.
  9. ^ a b c d e Wang J, Qu W, Bittenbender HC, et al. (2013). "Kavalactone content and chemotype of kava beverages prepared from roots and rhizomes of Isa and Mahakea varieties and extraction efficiency of kavalactones using different solvents". Journal of Food Science and Technology. 52 (2): 1164–1169. doi:10.1007/s13197-013-1047-2. PMC 4325077. PMID 25694734.
  10. ^ Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., Thomas, S., Teschke, R., Xing, C., & Sarris, J. (2015). Kava for the treatment of generalised anxiety disorder (K-GAD): Study protocol for a randomised controlled trial. Trials, 16, 493. https://doi.org/10.1186/s13063-015-0986-5
  11. ^ Barić, H., Đorđević, V., Cerovečki, I., & Trkulja, V. (2018). Complementary and alternative medicine treatments for generalized anxiety disorder: Systematic review and meta-analysis of randomized controlled trials. Advances in Therapy, 35(3), 261-288. https://doi.org/10.1007/s12325-018-0680-6
  12. ^ Smith, K., & Leiras, C. (2018). The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complementary Therapies in Clinical Practice, 33, 107-117. https://doi.org/10.1016/j.ctcp.2018.09.003
  13. ^ White, C. M. (2018). The pharmacology, pharmacokinetics, efficacy, and adverse events associated with kava. The Journal of Clinical Pharmacology, 58(11), 1396-1405. https://doi.org/10.1002/jcph.1263
  14. ^ Sarris, J., et al. (2020). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian & New Zealand Journal of Psychiatry, 54(3), 288-297. https://doi.org/10.1177/0004867419891246
  15. ^ Burton, N., Sneed, K. B., & Pathak, Y. (2023). Systemic review of the use of Kava Kava for the reduction of anxiety disorder. Medicon Medical Sciences, 5(2). Retrieved from https://themedicon.com/pdf/medicalsciences/MCMS-05-149.pdf
  16. ^ a b c d e "Kava: a review of the safety of traditional and recreational beverage consumption" (PDF). Food and Agriculture Organization of the United Nations and World Health Organization, Rome, Italy. 2016.
  17. ^ a b c d e f Kuchta K, Schmidt M, Nahrstedt A (1 December 2015). "German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics". Planta Medica. 81 (18): 1647–1653. doi:10.1055/s-0035-1558295. ISSN 1439-0221. PMID 26695707. S2CID 23708406.
  18. ^ Showman AF, Baker JD, Linares C, et al. (2015). "Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology". Fitoterapia. 100: 56–67. doi:10.1016/j.fitote.2014.11.012. PMID 25464054.
  19. ^ Applequist WL, Lebot V (25 April 2006). "Validation of Piper Methysticum var. wichmannii (Piperaceae)". Novon: A Journal for Botanical Nomenclature. 16 (1): 3–4. doi:10.3417/1055-3177(2006)16[3:VOPMVW]2.0.CO;2. S2CID 86552278.
  20. ^ a b c Ross M (2008). "Other cultivated plants". In Ross M, Pawley A, Osmond M (eds.). The lexicon of Proto Oceanic: The culture and environment of ancestral Oceanic society. Vol. 3. Pacific Linguistics. pp. 389–426. ISBN 978-0-85883-589-4.
  21. ^ Lebot V, Lèvesque J (1989). "The Origin and Distribution of Kava (Piper methysticum Forst. F., Piperaceae): A Phytochemical Approach". Allertonia. 5 (2): 223–281.
  22. ^ a b "*Kava ~ *Kavakava". Te Mära Reo: The Language Garden. Benton Family Trust. Retrieved 15 January 2019.
  23. ^ Blust R, Trussel S (2013). "The Austronesian Comparative Dictionary: A Work in Progress". Oceanic Linguistics. 52 (2): 493–523. doi:10.1353/ol.2013.0016. S2CID 146739541.
  24. ^ Lynch J (2002). "Potent Roots and the Origin of kava". Oceanic Linguistics. 41 (2): 493–513. doi:10.1353/ol.2002.0010. S2CID 145424062.
  25. ^ Heathcote GM, Diego VP, Ishida H, et al. (2012). "An osteobiography of a remarkable protohistoric Chamorro man from Taga, Tinian". Micronesica. 43 (2): 131–213.
  26. ^ McLean M (2014). Music, Lapita, and the Problem of Polynesian Origins. Polynesian Origins. ISBN 978-0-473-28873-0.
  27. ^ a b "Kawa ~ Kawakawa". Te Mära Reo: The Language Garden. Benton Family Trust. Retrieved 15 January 2019.
  28. ^ Vincent Lebot, Patricia Siméoni (2004). "Is the Quality of Kava (Piper methysticum Forst. f.) Responsible for Different Geographical Patterns?" (PDF). Ethnobotany Research & Applications. 2: 19–28. doi:10.17348/era.2.0.19-28.
  29. ^ Teschke R, Lebot V (1 October 2011). "Proposal for a Kava Quality Standardization Code". Food and Chemical Toxicology. 49 (10): 2503–2516. doi:10.1016/j.fct.2011.06.075. PMID 21756963.
  30. ^ "Drink the right mix - Fiji Times Online". www.fijitimes.com. Archived from the original on 30 June 2016. Retrieved 29 May 2016.
  31. ^ "Vanuatu hopes for kava export growth". Radio New Zealand. 11 November 2015. Retrieved 29 May 2016.
  32. ^ "Vanuatu kava cleared for European market". Radio New Zealand. 12 November 2015. Retrieved 29 May 2016.
  33. ^ a b c d Teschke R, Sarris J, Lebot V (15 January 2011). "Kava hepatotoxicity solution: A six-point plan for new kava standardization". Phytomedicine. 18 (2–3): 96–103. doi:10.1016/j.phymed.2010.10.002. PMID 21112196.
  34. ^ a b Johnston E, Rogers H, Association for Hawaiian ʻAwa (1 January 2006). Hawaiian ʻawa: views of an ethnobotanical treasure (PDF). Hilo, Hawaii: Association for Hawaiian ʻAwa. p. 34. OCLC 77501873.
  35. ^ "Kava vs Kawakawa | Kava use in New Zealand | Maori Memories of Kava". kavasociety.nz. Retrieved 2 July 2016.
  36. ^ "Māori Plant Use Database Plant Use Details of Macropiper excelsum". maoriplantuse.landcareresearch.co.nz. Archived from the original on 11 August 2016. Retrieved 2 July 2016.
  37. ^ a b c d Sarris J, LaPorte E, Schweitzer I (2011). "Kava: a comprehensive review of efficacy, safety, and psychopharmacology". Aust N Z J Psychiatry. 45 (1): 27–35. doi:10.3109/00048674.2010.522554. PMID 21073405. S2CID 42935399.
  38. ^ Bunchorntavakul C, Reddy KR (1 January 2013). "Review article: herbal and dietary supplement hepatotoxicity". Alimentary Pharmacology & Therapeutics. 37 (1): 3–17. doi:10.1111/apt.12109. ISSN 1365-2036. PMID 23121117. S2CID 6949220.
  39. ^ Olsen LR, Grillo MP, Skonberg C (2011). "Constituents in kava extracts potentially involved in hepatotoxicity: a review". Chem. Res. Toxicol. 24 (7): 992–1002. doi:10.1021/tx100412m. PMID 21506562.
  40. ^ a b c d e f g "Kava". Drugs.com. 3 January 2018. Retrieved 12 January 2018.
  41. ^ Singh YN, Singh NN (2002). "Therapeutic potential of kava in the treatment of anxiety disorders". CNS Drugs. 16 (11): 731–43. doi:10.2165/00023210-200216110-00002. PMID 12383029. S2CID 34322458.
  42. ^ Ligresti A, Villano R, Allarà M, et al. (2012). "Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand". Pharmacol. Res. 66 (2): 163–9. doi:10.1016/j.phrs.2012.04.003. PMID 22525682.
  43. ^ a b Dinh LD, Simmen U, Bueter KB, et al. (2001). "Interaction of various Piper methysticum cultivars with CNS receptors in vitro". Planta Med. 67 (4): 306–11. doi:10.1055/s-2001-14334. PMID 11458444. S2CID 260281694.
  44. ^ Amitava Dasgupta, Catherine A. Hammett-Stabler (2011). Herbal Supplements: Efficacy, Toxicity, Interactions with Western Drugs, and Effects on Clinical Laboratory Tests. John Wiley & Sons. p. 57. ISBN 978-0-470-92275-0.
  45. ^ Baum SS, Hill R, Rommelspacher H (1998). "Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats". Prog. Neuropsychopharmacol. Biol. Psychiatry. 22 (7): 1105–20. doi:10.1016/s0278-5846(98)00062-1. PMID 9829291. S2CID 24377397.
  46. ^ Garrett KM, Basmadjian G, Khan IA, et al. (2003). "Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice". Psychopharmacology. 170 (1): 33–41. doi:10.1007/s00213-003-1520-0. PMID 12845414. S2CID 10805207.
  47. ^ Cairney S, Clough AR, Maruff P, et al. (2003). "Saccade and cognitive function in chronic kava users". Neuropsychopharmacology. 28 (2): 389–96. doi:10.1038/sj.npp.1300052. PMID 12589393.
  48. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 803–804.
  49. ^ "Fiji -> In depth -> Food and Drink". www.frommers.com. Frommers. Retrieved 7 August 2014.
  50. ^ Viorica LA (1997). "Supercritical fluid extraction of kava lactones from Piper methysticum (kava) herb". Journal of High Resolution Chromatography. 20 (10): 555–559. doi:10.1002/jhrc.1240201007.
  51. ^ a b Teschke R, Sarris J, Glass X, et al. (2016). "Kava, the anxiolytic herb: back to basics to prevent liver injury?". British Journal of Clinical Pharmacology. 71 (3): 445–448. doi:10.1111/j.1365-2125.2010.03775.x. ISSN 0306-5251. PMC 3045554. PMID 21284704.
  52. ^ a b "Kava: A Human Health Risk Assessment" (PDF). Technical Report Series No 30. 25 May 2016. Archived from the original (PDF) on 11 February 2016. Retrieved 25 May 2016.
  53. ^ a b Organization WH (2007). Assessment of the Risk of Hepatotoxicity with Kava Products. WHO Regional Office Europe. ISBN 978-92-4-159526-1.
  54. ^ a b Kraft M, Spahn TW, Menzel J, et al. (2001). "Fulminantes Leberversagen nach Einnahme des pflanzlichen Antidepressivums Kava-Kava". Deutsche Medizinische Wochenschrift. 126 (36): 970–972. doi:10.1055/s-2001-16966. ISSN 0012-0472. PMID 11544547. S2CID 260067545.
  55. ^ Zhou P, Gross S, Liu JH, et al. (December 2010). "Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signaling pathways". The FASEB Journal. 24 (12): 4722–4732. doi:10.1096/fj.10-163311. ISSN 0892-6638. PMC 2992378. PMID 20696856.
  56. ^ a b Whitton PA, Lau A, Salisbury A, et al. (1 October 2003). "Kava lactones and the kava-kava controversy". Phytochemistry. 64 (3): 673–679. Bibcode:2003PChem..64..673W. doi:10.1016/S0031-9422(03)00381-9. ISSN 0031-9422. PMID 13679089.
  57. ^ Health (11 July 2011). "Australia New Zealand Food Standards Code - Standard 2.6.3 - Kava". www.legislation.gov.au. Retrieved 2 September 2018.
  58. ^ Biturogoiwasa S, Walker AR (2001). My Village, My World: Everyday Life in Nadoria, Fiji. Suva, Fiji: Institute of Pacific Studies, University of the South Pacific. pp. 17–20. ISBN 978-982-02-0160-6.
  59. ^ Tomlinson M (2007). "Everything and Its Opposite: Kava Drinking in Fiji". Anthropological Quarterly. 80 (4): 1065–81. doi:10.1353/anq.2007.0054. S2CID 144600224.[improper synthesis?]
  60. ^ Laterman K (22 December 2017). "In Brooklyn, a Hare Krishna Reckoning". The New York Times. Retrieved 22 December 2017.
  61. ^ Swanson J (20 March 2014). "South Florida Kava Bars Unworried about Two-Day Kava". Retrieved 28 July 2016.
  62. ^ a b Kilham C (1 June 1996). Kava: Medicine Hunting in Paradise: The Pursuit of a Natural Alternative to Anti-Anxiety Drugs and Sleeping Pills. Inner Traditions / Bear & Co. ISBN 978-0-89281-640-8.
  63. ^ Lebot V, Do TK, Legendre L (15 May 2014). "Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC)". Food Chemistry. 151: 554–560. doi:10.1016/j.foodchem.2013.11.120. ISSN 0308-8146. PMID 24423570.
  64. ^ Cairney S, Clough AR, Maruff P, et al. (14 February 2003). "Saccade and Cognitive Function in Chronic Kava Users". Neuropsychopharmacology. 28 (2): 389–396. doi:10.1038/sj.npp.1300052. ISSN 0893-133X. PMID 12589393.
  65. ^ LaPorte E, Sarris J, Stough C, et al. (1 March 2011). "Neurocognitive effects of kava (Piper methysticum): a systematic review". Human Psychopharmacology. 26 (2): 102–111. doi:10.1002/hup.1180. ISSN 1099-1077. PMID 21437989. S2CID 44657320.
  66. ^ Baker JD (1 June 2011). "Tradition and toxicity: evidential cultures in the kava safety debate". Social Studies of Science. 41 (3): 361–384. doi:10.1177/0306312710395341. ISSN 0306-3127. PMID 21879526. S2CID 33364504.
  67. ^ Kilham CS (1 June 1996). Kava: Medicine Hunting in Paradise: The Pursuit of a Natural Alternative to Anti-Anxiety Drugs and Sleeping Pills. Inner Traditions / Bear & Co. ISBN 978-1-62055-034-2.
  68. ^ Lebot V, Lèvesque J (1 January 1989). "The origin and distribution of kava (Piper methysticum Forst. F., Piperaceae): A phytochemical approach". Allertonia. 5 (2): 223–281. JSTOR 23187398.
  69. ^ Sarris J, Stough C, Teschke R, et al. (1 November 2013). "Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects". Phytotherapy Research. 27 (11): 1723–1728. doi:10.1002/ptr.4916. ISSN 1099-1573. PMID 23348842. S2CID 19526418.
  70. ^ Brown AC (September 2017). "Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series". Food Chem Toxicol (Review). 107 (Pt A): 472–501. doi:10.1016/j.fct.2016.07.001. PMID 27402097.
  71. ^ Teschke R, Schulze J (2010). "Risk of Kava Hepatotoxicity and the FDA Consumer Advisory". JAMA. 304 (19): 2174–5. doi:10.1001/jama.2010.1689. ISSN 0098-7484. PMID 21081732.
  72. ^ Cairney S., Maruff P., Clough A. R., et al. (2003). "Saccade and cognitive impairment associated with kava intoxication". Hum. Psychopharmacol. 18 (7): 525–533. doi:10.1002/hup.532. PMID 14533134. S2CID 21555220.
  73. ^ a b Spinella M (2002). "The importance of pharmacological synergy in psychoactive herbal medicines". Altern Med Rev. 7 (2): 130–137. PMID 11991792.
  74. ^ Hu Z, Yang X, Ho PC, et al. (2005). "Herb-drug interactions: a literature review". Drugs. 65 (9): 1239–82. doi:10.2165/00003495-200565090-00005. PMID 15916450. S2CID 46963549.
  75. ^ Lees AJ (1989). "The on-off phenomenon". J Neurol Neurosurg Psychiatry. Suppl (9): 29–37. doi:10.1136/jnnp.52.suppl.29. PMC 1033307. PMID 1033307.
  76. ^ Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review" Drugs 2001;61(15):2163-75.
  77. ^ Ruze P (16 June 1990). "Originally published as Volume 1, Issue 8703Kava-induced dermopathy: a niacin deficiency?". The Lancet. 335 (8703): 1442–1445. doi:10.1016/0140-6736(90)91458-M. PMID 1972218. S2CID 9737032.
  78. ^ a b c Norton SA, Ruze P (1 July 1994). "Kava dermopathy". Journal of the American Academy of Dermatology. 31 (1): 89–97. doi:10.1016/S0190-9622(94)70142-3. PMID 8021378.
  79. ^ "Kava Side Effects". The Kava Library. Retrieved 8 September 2017.
  80. ^ Jappe U, Franke I, Reinhold D, et al. (1998). "Sebotropic drug reaction resulting from kava-kava extract therapy: A new entity?". Journal of the American Academy of Dermatology. 38 (1): 104–6. doi:10.1016/S0190-9622(98)70547-X. PMID 9448214.
  81. ^ Wheatley D (1 June 2001). "Stress-induced insomnia treated with kava and valerian: singly and in combination". Human Psychopharmacology. 16 (4): 353–356. doi:10.1002/hup.299. ISSN 1099-1077. PMID 12404572. S2CID 37457833.
  82. ^ Pittler MH, Ernst E (2003). Pittler MH (ed.). "Kava extract for treating anxiety". Cochrane Database of Systematic Reviews. 2003 (1): CD003383. doi:10.1002/14651858.CD003383. PMC 6999799. PMID 12535473.
  83. ^ a b Showman AF, Baker JD, Linares C, et al. (1 January 2015). "Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology". Fitoterapia. 100: 56–67. doi:10.1016/j.fitote.2014.11.012. ISSN 1873-6971. PMID 25464054.
  84. ^ "Australia New Zealand Food Standards Code - Standard 2.6.3 - Kava". Federal Register of Legislation. 5 October 2006. Retrieved 22 October 2016.
  85. ^ "Travelers from Fiji to Australia can now take more kava for social functions". Xinhua. 17 December 2019. Archived from the original on 17 December 2019. Retrieved 21 January 2020.
  86. ^ "Import requirements: Kava". The Office of Drug Control, Department of Health, Government of Australia. 1 December 2021. Retrieved 7 February 2022..
  87. ^ "Kava fact sheet". Therapeutic Goods Administration, Government of Australia. April 2005. Archived from the original on 20 July 2006. Retrieved 10 July 2006. (Download PDF 44KB Archived 20 August 2006 at the Wayback Machine).
  88. ^ "Kava". Northern Territory Government. 12 December 2016. Retrieved 14 February 2017.
  89. ^ Armbruster, Stefan (10 July 2015). "Islanders shocked as Australia moves to ban kava". Special Broadcasting Service (SBS), Sydney. Retrieved 14 February 2017.
  90. ^ "Kava legal in WA, marketed at troubled sleepers". The West Australian. 13 February 2017. Retrieved 13 February 2017.
  91. ^ C.I.J.M. Ross-van Dorp (2003). "Besluit van 23 april 2003, houdende wijziging van het Warenwetbesluit Kruidenpreparaten (verbod op Kava kava in kruidenpreparaten)" (PDF). Sdu Uitgevers. Staatsblad van het Koninkrijk der Nederlanden. Archived from the original (PDF) on 27 February 2008. Retrieved 7 February 2007.
  92. ^ "Fiji takes kava ban fight to WTO". The World Trade Review. August 2005. Archived from the original on 29 October 2013. Retrieved 26 October 2013.
  93. ^ Bowman C. "The Pacific Island Nations: Towards Shared Representation". WTO. Retrieved 26 October 2013.
  94. ^ "Comeback unter strengen Auflagen" (in German). Pharmazeutische Zeitung. 16 August 2015. Retrieved 25 July 2021.
  95. ^ Joshua J (17 February 2016). "New Kava Challenge". Vanuatu Daily Post. Retrieved 12 June 2023.
  96. ^ "The Medicines for Human Use (Kava-kava) (Prohibition) Order 2002". Legislation.gov.uk. Retrieved 26 October 2013.
  97. ^ Garae L (27 December 2017). "Kava banned in Poland". Vanuatu Daily Post. Retrieved 2 September 2018.
  98. ^ "Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych". prawo.sejm.gov.pl (in Polish). Retrieved 12 June 2023.
  99. ^ "Kava zalegalizowana. Marihuana będzie następna?". www.rp.pl (in Polish). Retrieved 12 December 2018.
  100. ^ Koninkrijksrelaties Mv. "Warenwetbesluit Kruidenpreparaten". wetten.overheid.nl.
  101. ^ "Dunne: Kava unaffected by Psychoactive Substances Bill". The Beehive. Retrieved 24 October 2016.
  102. ^ "Standard 2.6.3 – Kava – Food Standards (Proposal P1025 – Code Revision) Variation—Australia New Zealand Food Standards Code – Amendment No. 154 - 2015-gs1906 - New Zealand Gazette". gazette.govt.nz. Retrieved 2 July 2016.
  103. ^ "Marketed Health Products Directorate Heath Products and Foods Branch". Canadian Adverse Reaction Newsletter. 12 (4). 2002.
  104. ^ "Listing of Drugs Currently Regulated as New Drugs (The New Drugs List)". www.hc-sc.gc.ca. Health Canada. 26 May 2016. Retrieved 3 July 2017.
  105. ^ "Kava". HealthLink BC, Government of British Columbia. 23 September 2021. Retrieved 3 March 2022.
  106. ^ "Ingredients - Kava". Health Canada. 2017. Archived from the original on 11 August 2022. Retrieved 1 July 2017.
  107. ^ "Consumer Advisory: Kava-Containing Dietary Supplements May be Associated with Severe Liver Injury". US Food and Drug Administration. 25 March 2002. Archived from the original on 3 June 2009. Retrieved 28 June 2020.
  108. ^ "Vanuatu - Legislation - Kava Act 2002". faolex.fao.org. Retrieved 2 July 2016.
[edit]
Wikispecies has information related to Piper methysticum.
Wikisource has the text of the 1911 Encyclopædia Britannica article "Kava".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kava&oldid=1264339261"